JP2008115147A - 脂質−スペーサ−官能基−ペプチドを製造する方法 - Google Patents

脂質−スペーサ−官能基−ペプチドを製造する方法 Download PDF

Info

Publication number
JP2008115147A
JP2008115147A JP2006350627A JP2006350627A JP2008115147A JP 2008115147 A JP2008115147 A JP 2008115147A JP 2006350627 A JP2006350627 A JP 2006350627A JP 2006350627 A JP2006350627 A JP 2006350627A JP 2008115147 A JP2008115147 A JP 2008115147A
Authority
JP
Japan
Prior art keywords
peptide
spacer
lipid
functional group
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006350627A
Other languages
English (en)
Japanese (ja)
Inventor
Te-Wei Lee
徳偉 李
Shu-Pei Chiu
淑珮 邱
Chiu-Yu Yu
佳瑜 游
Tsui-Jung Chang
翠容 張
Chih-Hsien Chang
志賢 張
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Nuclear Energy Research
Original Assignee
Institute of Nuclear Energy Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Nuclear Energy Research filed Critical Institute of Nuclear Energy Research
Publication of JP2008115147A publication Critical patent/JP2008115147A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2006350627A 2006-10-31 2006-12-26 脂質−スペーサ−官能基−ペプチドを製造する方法 Pending JP2008115147A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW095140210A TW200819137A (en) 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide

Publications (1)

Publication Number Publication Date
JP2008115147A true JP2008115147A (ja) 2008-05-22

Family

ID=39330477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006350627A Pending JP2008115147A (ja) 2006-10-31 2006-12-26 脂質−スペーサ−官能基−ペプチドを製造する方法

Country Status (3)

Country Link
US (2) US20080102110A1 (https=)
JP (1) JP2008115147A (https=)
TW (1) TW200819137A (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521389A (ja) * 2009-03-25 2012-09-13 ノバルティス アーゲー 薬物及びｓｉＲＮＡを含有する医薬組成物
JP2013515767A (ja) * 2009-12-29 2013-05-09 キョンブク ナショナル ユニバーシティ インダストリー−アカデミック コーオペレーション ファウンデーション インターロイキン−４受容体を特異的に標的とするペプチドで標識されたリポソームを含有する癌診断又は治療用標的指向型薬物伝達システム、及びその製造方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10611796B2 (en) 2016-03-16 2020-04-07 Council Of Scientific & Industrial Research Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5690048A (en) * 1979-11-27 1981-07-21 Sandoz Ag Novel polypeptides* their manufacture* medicinal composition containing them and their use
WO1997031624A1 (en) * 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
EP1118336A2 (en) * 2000-01-13 2001-07-25 Academia Sinica Somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
JP2002535290A (ja) * 1999-01-21 2002-10-22 ジョージタウン・ユニバーシティ ターゲッティングした遺伝子移入のためのリガンド−ｐｅｇポストコート安定化したリポプレックスおよびポリプレックス

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0445606B1 (en) * 1990-02-27 1997-01-22 The Agency of Industrial Science and Technology Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides
CA2422707A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5690048A (en) * 1979-11-27 1981-07-21 Sandoz Ag Novel polypeptides* their manufacture* medicinal composition containing them and their use
WO1997031624A1 (en) * 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
JP2002535290A (ja) * 1999-01-21 2002-10-22 ジョージタウン・ユニバーシティ ターゲッティングした遺伝子移入のためのリガンド−ｐｅｇポストコート安定化したリポプレックスおよびポリプレックス
EP1118336A2 (en) * 2000-01-13 2001-07-25 Academia Sinica Somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521389A (ja) * 2009-03-25 2012-09-13 ノバルティス アーゲー 薬物及びｓｉＲＮＡを含有する医薬組成物
JP2013515767A (ja) * 2009-12-29 2013-05-09 キョンブク ナショナル ユニバーシティ インダストリー−アカデミック コーオペレーション ファウンデーション インターロイキン−４受容体を特異的に標的とするペプチドで標識されたリポソームを含有する癌診断又は治療用標的指向型薬物伝達システム、及びその製造方法

Also Published As

Publication number Publication date
US20080139703A1 (en) 2008-06-12
TW200819137A (en) 2008-05-01
US20080102110A1 (en) 2008-05-01
TWI362270B (https=) 2012-04-21

Similar Documents

Publication Publication Date Title
JP3920330B2 (ja) ポリエチレングリコール変性されたセラミド脂質類及びそれらのリポソームへの使用
Said Hassane et al. Targeted liposomes: convenient coupling of ligands to preformed vesicles using “click chemistry”
JP3688278B2 (ja) 自己構築ポリヌクレオチド送達システム
US6320017B1 (en) Polyamide oligomers
FI94419C (fi) Menetelmä terapeuttisesti käyttökelpoisen membraaniankkuri-vaikuttava-ainekonjugaatin valmistamiseksi
EP1041976B1 (en) Polyamide oligomers
US5738867A (en) Antitumor vaccines
CN103550781A (zh) 树状大分子自组装药物载体及其制备方法和应用
JP5093547B2 (ja) 両イオン性脂質およびその用途
US20070140972A1 (en) Targeting compositions and preparation therof
US6194543B1 (en) Dendritic polypeptides
EP4424701A1 (en) Cyclic polypeptide carrier for efficient delivery of nucleic acid, and variants thereof
JP2008115147A (ja) 脂質−スペーサ−官能基−ペプチドを製造する方法
KR20190118983A (ko) pH 감응성 펩타이드 구조체, 및 이의 용도
Accardo et al. Liposomes derivatized with tetrabranched neurotensin peptides via click chemistry reactions
CN111166892A (zh) 生物素和穿膜肽共同介导的乳腺癌靶向智能脂质体材料
WO2024041372A1 (zh) 一种用于有效递送核酸的分支链结构多肽载体及其变化形式
EP1935433A1 (en) A method for preparing covalent lipid-spacer-peptide conjugates
KR101927949B1 (ko) 다중성분 기반의 다중 베시클, 이의 용도 및 이를 제조하는 방법
CN120899934B (zh) 一种免疫调控手性材料及其制备方法与应用
JP2003506335A (ja) マンノースレセプターリガンドを調製するためのキナ酸、シキミ酸およびそれらの誘導体の使用
CN113164613B (zh) 二聚的肽-磷脂缀合物的优化方法
CN113368256A (zh) 分枝葡萄糖和生物素介导的脑胶质瘤靶向智能脂质体材料
CN121021329A (zh) 两类功能性肽脂质化合物及三组分纳米颗粒与应用
CN117843712A (zh) 一种小肽脂质纳米递送系统及其应用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100812